ADGI
Price:
$4.64
Market Cap:
$61.18M
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. T...[Read more]
Industry
Biotechnology
IPO Date
2021-08-06
Stock Exchange
NASDAQ
Ticker
ADGI
According to Adagio Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -144.67%. This represents a change of 265.53% compared to the average of -39.58% of the last 4 quarters.
The mean historical ROE of Adagio Therapeutics, Inc. over the last ten years is -74.26%. The current -144.67% ROE has changed 94.80% with respect to the historical average. Over the past ten years (40 quarters), ADGI's ROE was at its highest in in the March 2021 quarter at 37.44%. The ROE was at its lowest in in the September 2024 quarter at -73.04%.
Average
-74.26%
Median
-65.91%
Minimum
-251.60%
Maximum
100.11%
Discovering the peaks and valleys of Adagio Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 124.78%
Maximum Annual ROE = 100.11%
Minimum Annual Increase = -141.94%
Minimum Annual ROE = -251.60%
Year | ROE | Change |
---|---|---|
2024 | -251.60% | 124.78% |
2023 | -111.93% | 69.84% |
2022 | -65.91% | 56.97% |
2021 | -41.99% | -141.94% |
The current ROE of Adagio Therapeutics, Inc. (ADGI) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-143.14%
5-year avg
-74.26%
10-year avg
-74.26%
Adagio Therapeutics, Inc.’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Adagio Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Adagio Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Adagio Therapeutics, Inc.'s ROE?
How is the ROE calculated for Adagio Therapeutics, Inc. (ADGI)?
What is the highest ROE for Adagio Therapeutics, Inc. (ADGI)?
What is the 3-year average ROE for Adagio Therapeutics, Inc. (ADGI)?
What is the 5-year average ROE for Adagio Therapeutics, Inc. (ADGI)?
How does the current ROE for Adagio Therapeutics, Inc. (ADGI) compare to its historical average?